Relevant disclosure attached

AI summary - Q1 FY27 consolidated revenue grew 17.5% y-y to INR 2,545 Cr; hospital revenue +19%, diagnostics +10.2% - Consolidated operating EBITDA pre-ESOP rose 15.8% to INR 568 Cr; margin 22.3% vs 22.6% in Q1 FY26 - Diagnostics EBITDA margin improved to 23.9% from 23%; gross revenue INR 407 Cr - Net debt INR 2,233 Cr; net debt/EBITDA 1.01x; acquisitions increased debt - Hospital occupancy steady at 69%; 100 new beds added; oncology expansion ongoing - Capex includes proton therapy (~INR 252 Cr) and robotic surgery investments - FY27 hospital EBITDA margin target 25% including ESOP cost; ESOP charge ~INR 40 Cr/qtr initially - Diagnostics revenue growth guidance 12-13%, EBITDA margin 24-25% - Inorganic growth focused on existing clusters; O&M agreements progressing - Multiple analyst queries on ESOP impact, margin levers, and expansion plans addressed